A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL
Completed · Phase 2
Conditions studied: Leukemia
In brief
RATIONALE: Monoclonal antibodies, such as alemtuzumab and rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving alemtuzumab together with rituximab may kill more cancer cells. PURPOSE: This phase II trial is studying the side effects of giving alemtuzumab together with rituximab and to see how well it works in treating patients with previously untreated B-cell chronic lymphocytic leukemia.
Key facts
- Study ID
- NCT00858117
- Run by
- Northwestern University
- People needed
- 30
- Starts
- 2005-09-26
- Expected to finish
- 2013-01-24
- Last updated by the study team
- 2020-11-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Northwestern University, Northwestern Medical Faculty Foundation — Chicago, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.